Hologic Inc. (NASDAQ:HOLX) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,461,519 shares, an increase of 61.3% from the September 15th total of 4,006,600 shares. Based on an average daily volume of 2,410,185 shares, the short-interest ratio is presently 2.7 days. Currently, 2.3% of the company’s shares are short sold.

Several research firms recently issued reports on HOLX. Piper Jaffray Cos. set a $44.00 target price on shares of Hologic and gave the company a “hold” rating in a report on Sunday, August 28th. BTIG Research restated a “buy” rating and issued a $44.00 target price on shares of Hologic in a report on Thursday, July 28th. RBC Capital Markets restated a “sector perform” rating and issued a $39.00 target price (up previously from $37.00) on shares of Hologic in a report on Monday, August 1st. Leerink Swann restated a “buy” rating and issued a $46.00 target price on shares of Hologic in a report on Thursday, July 28th. Finally, Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Six research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $42.71.

Shares of Hologic (NASDAQ:HOLX) opened at 38.81 on Thursday. The firm has a 50-day moving average of $38.49 and a 200-day moving average of $36.32. Hologic has a 12 month low of $31.84 and a 12 month high of $41.66. The company has a market capitalization of $10.77 billion, a P/E ratio of 42.79 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The firm earned $717.40 million during the quarter, compared to analysts’ expectations of $703.66 million. During the same period last year, the company posted $0.43 EPS. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. On average, equities analysts predict that Hologic will post $1.94 earnings per share for the current year.

In related news, Director Elaine Ullian sold 18,236 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $39.88, for a total value of $727,251.68. Following the transaction, the director now owns 42,898 shares in the company, valued at $1,710,772.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Nancy Leaming sold 8,179 shares of the business’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the transaction, the director now owns 67,140 shares in the company, valued at approximately $2,484,180. The disclosure for this sale can be found here. Insiders own 0.84% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Mizuho Asset Management Co. Ltd. boosted its stake in Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock valued at $115,000 after buying an additional 1,568 shares in the last quarter. J.Safra Asset Management Corp bought a new stake in Hologic during the second quarter valued at approximately $115,000. Invictus RG boosted its stake in Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock valued at $131,000 after buying an additional 3,231 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its stake in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock valued at $144,000 after buying an additional 51 shares in the last quarter. Finally, Synovus Financial Corp boosted its stake in Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock valued at $171,000 after buying an additional 1,300 shares in the last quarter. 94.51% of the stock is owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.